Spots Global Cancer Trial Database for phase iii
Every month we try and update this database with for phase iii cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | NCT04964934 | ER-Positive HER... | AZD9833 AZD9833 Placebo Anastrozole Anastrozole pla... Letrozole Letrozole place... Palbociclib Abemaciclib Luteinizing hor... Ribociclib | 18 Years - 130 Years | AstraZeneca | |
| Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC) | NCT01135056 | Hepatocellular ... | SIR-Spheres Sorafenib tosyl... | 18 Years - | Singapore General Hospital | |
| A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | NCT04711252 | ER-Positive HER... | AZD9833 Anastrozole Anastrozole pla... AZD9833 placebo Palbociclib Luteinizing hor... | 18 Years - 130 Years | AstraZeneca | |
| A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection | NCT01402908 | Cancer Liver Cancer Hepatocellular ... | PI-88 Placebo | 18 Years - | Cellxpert Biotechnology Corp. | |
| Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer | NCT00128531 | Prostate Cancer | leuprolide acet... | 18 Years - | GP-Pharm | |
| Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) | NCT04266301 | Myelodysplastic... Leukemia, Myelo... | Sabatolimab Azacitidine Placebo | 18 Years - | Novartis | |
| CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers | NCT00822809 | Cancer Neoplasms Carcinoma Malignant Ascit... | Catumaxomab Prednisolone | 18 Years - | Neovii Biotech | |
| Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) | NCT01170650 | Ovarian Cancer | EC145 Pegylated Lipos... placebo EC20 | 18 Years - | Endocyte | |
| S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer | NCT01809691 | Prostate Cancer | TAK-700 Bicalutamide | 18 Years - | SWOG Cancer Research Network | |
| AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | NCT06346392 | Gastric Cancer Gastroesophagea... | AZD0901 AZD0901 Ramucirumab+ pa... Paclitaxel Docetaxel Irinotecan TAS-102 Apatinib | 18 Years - 130 Years | AstraZeneca | |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | NCT02437318 | Breast Cancer | Fulvestrant Alpelisib Alpelisib place... | 18 Years - | Novartis | |
| International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) | NCT02305654 | Squamous Cell C... | ILND - Inguinal... Paclitaxel Ifosfamide Cisplatin Intensity modul... Prophylactic PL... | 18 Years - | Institute of Cancer Research, United Kingdom | |
| Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut | NCT00171873 | Neuroendocrine ... | Octreotide LAR ... Placebo | 18 Years - | Philipps University Marburg Medical Center | |
| Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) | NCT04266301 | Myelodysplastic... Leukemia, Myelo... | Sabatolimab Azacitidine Placebo | 18 Years - | Novartis | |
| Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) | NCT01147939 | Acute Myeloid L... | Elacytarabine Investigator's ... | 18 Years - | Clavis Pharma | |
| A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients | NCT03013504 | HER2 Positive B... | HD201 Herceptin Docetaxel Epirubicin Cyclophosphamid... | 18 Years - | Prestige Biopharma Limited | |
| IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer | NCT00316745 | Metastatic Colo... | Campto, Topotes... TS-1 L-Plat Isovorin 5-FU | 18 Years - 75 Years | Hokkaido Gastrointestinal Cancer Study Group | |
| Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) | NCT01147939 | Acute Myeloid L... | Elacytarabine Investigator's ... | 18 Years - | Clavis Pharma | |
| Trial in Low Grade Glioma Patients: Wait or Treat | NCT03763422 | Low-grade Gliom... Temozolomide Phase III Wait or Treat | Temozolomide Radiotherapy Surgery | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma | NCT02155634 | Multiple Myelom... Neoplasms Plasma Cells Paraproteinemia... Blood Protein D... Hematologic Dis... Therapeutic Use... | Lenalidomide | 18 Years - | Celgene | |
| A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT01578707 | Relapsed or Ref... Small Lymphocyt... | ofatumumab ibrutinib | 18 Years - | Pharmacyclics LLC. | |
| Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. | NCT02437318 | Breast Cancer | Fulvestrant Alpelisib Alpelisib place... | 18 Years - | Novartis | |
| Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma | NCT00689936 | Multiple Myelom... | Lenalidomide an... Lenalidomide pl... Melphalan, Pred... | 18 Years - | Celgene | |
| Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients | NCT01040780 | Non-small Cell ... | Icotinib Gefitinib | 18 Years - 75 Years | Betta Pharmaceuticals Co., Ltd. | |
| Trial in Low Grade Glioma Patients: Wait or Treat | NCT03763422 | Low-grade Gliom... Temozolomide Phase III Wait or Treat | Temozolomide Radiotherapy Surgery | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC | NCT03366883 | Esophageal Canc... Esophageal Canc... | Paclitaxel, Cis... radiochemothera... | 20 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve | NCT00225290 | Carcinoma, Hepa... | Thalidomide(Tha... | 20 Years - | TTY Biopharm | |
| FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer | NCT01219920 | Metastatic Colo... | FOLFIRI FOLFOXIRI | 18 Years - 75 Years | Gruppo Oncologico del Nord-Ovest | |
| Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | NCT04964934 | ER-Positive HER... | AZD9833 AZD9833 Placebo Anastrozole Anastrozole pla... Letrozole Letrozole place... Palbociclib Abemaciclib Luteinizing hor... Ribociclib | 18 Years - 130 Years | AstraZeneca | |
| GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer | NCT05054751 | Locally Advance... | GB491+ Fulvestr... Placebo+Fulvest... | 18 Years - | Genor Biopharma Co., Ltd. | |
| Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) | NCT01147939 | Acute Myeloid L... | Elacytarabine Investigator's ... | 18 Years - | Clavis Pharma | |
| Hydralazine Valproate for Cervical Cancer | NCT00532818 | Metastatic Cerv... | Hydralazine and... Placebo | 18 Years - | National Institute of Cancerología | |
| Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients | NCT00417911 | Multiple Myelom... | bortezomib | 18 Years - | Nordic Myeloma Study Group | |
| Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) | NCT01170650 | Ovarian Cancer | EC145 Pegylated Lipos... placebo EC20 | 18 Years - | Endocyte | |
| Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance | NCT00367861 | Sarcoma Gastro-intestin... | interruption of... | 18 Years - | Centre Leon Berard | |
| A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients | NCT03013504 | HER2 Positive B... | HD201 Herceptin Docetaxel Epirubicin Cyclophosphamid... | 18 Years - | Prestige Biopharma Limited | |
| Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study | NCT05904119 | First Progressi... | Lomustine Reirradiation | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) | NCT04266301 | Myelodysplastic... Leukemia, Myelo... | Sabatolimab Azacitidine Placebo | 18 Years - | Novartis | |
| Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients | NCT01040780 | Non-small Cell ... | Icotinib Gefitinib | 18 Years - 75 Years | Betta Pharmaceuticals Co., Ltd. | |
| A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations | NCT05157776 | NSCLC, Stage II... EGF-R Negative ... ALK Negative NS... | PD-1 and chemot... | 18 Years - 75 Years | Tongji University | |
| Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve | NCT00225290 | Carcinoma, Hepa... | Thalidomide(Tha... | 20 Years - | TTY Biopharm | |
| Hydralazine Valproate for Cervical Cancer | NCT00532818 | Metastatic Cerv... | Hydralazine and... Placebo | 18 Years - | National Institute of Cancerología | |
| Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma | NCT00689936 | Multiple Myelom... | Lenalidomide an... Lenalidomide pl... Melphalan, Pred... | 18 Years - | Celgene | |
| AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | NCT06346392 | Gastric Cancer Gastroesophagea... | AZD0901 AZD0901 Ramucirumab+ pa... Paclitaxel Docetaxel Irinotecan TAS-102 Apatinib | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
